basic fibroblast growth factor  (R&D Systems)

Journal: Materials Today Bio

Article Title: Multidimensional nano-ion composite hydrogel based on enzymatic blood glucose control, gas therapy and ion liquid permeation for repairing diabetic wounds

doi: 10.1016/j.mtbio.2026.103213

Figure Lengend Snippet: Skin immunofluorescence staining and immunohistochemical analysis were performed in different treatment groups. A) Immunofluorescence staining images of NF200. β 3 -Tubulin. PGP9.5. CD31. VEGF and IL-6 in skin wounds on the 14th day after treatment. Scale = 400 μm. B) Immunohistochemical images of FGF2 on day 14 in wound tissue. Scale = 400 μm. C) Images of the immunohistochemistry of AGEs. Scale bar = 400 μm. D) Fluorescence intensity of NF200. E) Fluorescence intensity of β 3 Tubulin. F) Fluorescence intensity of PGP9.5. G) CD31-labeled micro vessel density. H) Fluorescence intensity of VEGF. I) Fluorescence intensity of IL-6. J) Integrated option density (IOD) of FGF2. K) IOD of AGEs. Data are represented as mean ± SD (n = 3). Statistical analysis was performed using one-way analysis of variance (ANOVA) followed by Tukey's test ∗ p < 0.05. ∗∗ p < 0.01. ∗∗∗ p < 0.001. ∗∗∗∗ p < 0.0001.

Article Snippet: After routine deparaffinization, rehydration, and antigen retrieval, the sections were blocked and then incubated overnight at 4 °C with primary antibodies against FGF2 (1:500, GB113751 , Servicebio) and AGEs (1:200, bs-1158R, BIOSS).

Techniques: Immunofluorescence, Staining, Immunohistochemical staining, Immunohistochemistry, Fluorescence, Labeling

Journal: Journal of Human Immunity

Article Title: Human ISG15 deficiency unveils impaired healing of ulcerations via type I interferon–mediated fibrosis

doi: 10.70962/jhi.20250011

Figure Lengend Snippet: Myofibroblast activation in ISG15-deficient cells. (A) Spatial expression and intensity levels of two myofibroblast markers ( ACTA2 and COL5A1 ). (B) Relative expression of various myofibroblast markers for clusters 1 and 5 separated by sample biopsy. (C) Percentage of total spots that express TGFβ in the entire biopsy, within CD68 + spots only, and within myofibroblast cluster 5. (D) Significance of pathway enrichment for clusters 0, 1, 5, 3, 7, and 9 generated by MSigDB Hallmark 2020 and BioPlanet 2019 analysis from Enrichr. Adjusted P values are shown. (E) Relative RNA levels of myofibroblast markers ( PDGFA , ITGB6 , FGF2 ) following a 72-h treatment with 1,000 IU/ml IFNα2b, 10 ng/ml TGFβ, or both of WT and ISG15 KO lung epithelial cells (A549). (F) Percentage of cells undergoing EMT upon TGFβ/IFNα stimulation. (G) Relative RNA levels of myofibroblast markers ( PDGFA , ITGB6 , FGF2 ) following a 5-day treatment with 1,000 IU/ml IFNα2b, 10 ng/ml TGFβ, or both of WT and ISG15 KO fibroblasts. (H) ACTA2 (myofibroblasts) IHC for lesion 1 and lesion 3. P values were calculated with two-tailed t test. *P < 0.05.

Article Snippet: The probes used were the following: TGFB1 Hs07289533_m1, ISG15 Hs01921425_s1, IFIT1 Hs03027069_s1, IFI27 Hs01086373_g1, SIGLEC1 Hs00988063_m1, MX1 Hs00895608_m1, FGF-2 Hs00266645_m1, ITGB6 Hs00168458_m1, PDGFA Hs00234994_m1.

Techniques: Activation Assay, Expressing, Generated, Two Tailed Test